Autolus Therapeutics plc (AUTL)

Market Cap	489.70M
Revenue (ttm)	29.93M
Net Income (ttm)	-227.78M
Shares Out	266.14M
EPS (ttm)	-0.87
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,961,921
Open	2.150
Previous Close	2.155
Day's Range	1.825 - 2.185
52-Week Range	1.105 - 5.000
Beta	1.90
Analysts	Strong Buy
Price Target	9.12 (+395.65%)
Earnings Date	Aug 12, 2025

About AUTL

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally. The company’s clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 22, 2018
• Employees: 650
• Stock Exchange: NASDAQ
• Ticker Symbol: AUTL
• Website: https://www.autolus.com

Financial Performance

In 2024, Autolus Therapeutics's revenue was $10.12 million, an increase of 496.00% compared to the previous year's $1.70 million. Losses were -$220.66 million, 5.89% more than in 2023.

Analyst Forecast

According to 5 analysts, the average rating for AUTL stock is "Strong Buy." The 12-month stock price target is $9.12, which is an increase of 395.65% from the latest price.

Price Target

$9.12

(395.65% upside)

Analyst Consensus: Strong Buy